Olanzapine (Zyprexa Relprevv) vs Paliperidone (Invega)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (Zyprexa Relprevv)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00088478 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.
Reported efficacy
Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)
Result source: NCT00088478
Paliperidone (Invega)
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT04478838 (registry estimate)
Reported efficacy
Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)
Result source: NCT04072575
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Olanzapine (Zyprexa Relprevv) | Paliperidone (Invega) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00088491 | -9.8 vs -7.9−1.9 vs placeboNCT005183238 other results
|
| CGI-S, change | -0.4 vs -0.3vs Oral OlanzapineNCT00320489 | 0 vs 0±0 vs placeboNCT005183237 other results
|
| PANSS response | —Not posted · NCT00088491 | 76.8% vs 81.6%vs AripiprazoleNCT010090471 other result
|
| PSP, change | —Not posted · NCT00088491 | 17.1 vs 17.1vs AripiprazoleNCT010090473 other results
|
| Relapse (% of patients) | 20.1% vs 18.5%vs Oral OlanzapineNCT00320489 | —Not posted · NCT03485417 |
PANSS total, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Paliperidone (Invega)
- -9.8 vs -7.9−1.9 vs placeboNCT00518323
8 other results
- -17.3 vs -7.9 NCT00518323
- -13.8 vs -7.9 NCT00518323
- -9.1 vs 3.8 NCT00396565
- -19.3 vs -19.8 NCT01009047
- -25.6 vs -26.8 NCT01009047
- -13.5 vs -16.6 NCT00645099
- -15 vs -11.7 NCT00524043
- -8.9 vs -11.7 NCT00524043
CGI-S, change
- Olanzapine (Zyprexa Relprevv)
- -0.4 vs -0.3vs Oral OlanzapineNCT00320489
- Paliperidone (Invega)
- 0 vs 0±0 vs placeboNCT00518323
7 other results
- -1 vs 0 NCT00518323
- -1 vs 0 NCT00518323
- -0.4 vs 0.2 NCT00396565
- -1 vs -1 NCT01009047
- -1 vs -1 NCT01009047
- -0.5 vs -1 NCT00524043
- 0 vs -1 NCT00524043
PANSS response
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Paliperidone (Invega)
- 76.8% vs 81.6%vs AripiprazoleNCT01009047
1 other result
- 67.9% vs 76.3% NCT01009047
PSP, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Paliperidone (Invega)
- 17.1 vs 17.1vs AripiprazoleNCT01009047
3 other results
- 12.2 vs 12.2 NCT01009047
- 5.7 vs 1.6 NCT00524043
- 2.9 vs 1.6 NCT00524043
Relapse (% of patients)
- Olanzapine (Zyprexa Relprevv)
- 20.1% vs 18.5%vs Oral OlanzapineNCT00320489
- Paliperidone (Invega)
- —Not posted · NCT03485417
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. Olanzapine (Zyprexa Relprevv): 8 of 8 rows · Paliperidone (Invega): 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olanzapine (Zyprexa Relprevv) Rows use multiple source trials | Paliperidone (Invega) Rows use multiple source trials |
|---|---|---|
| CGI-S absolute change · score No placebo or comparator arm | -0.17 score @ 313wka,b,c NCT00088465 · Phase 3 · registry result, not featured evidence | -1 score @ 104wkd,a,b,c NCT00488319 · Phase 3 · registry result, not featured evidence show 2 more doses-1 score @ 104wk NCT00488319 · Phase 3 · registry result, not featured evidence -1 score @ 104wk NCT00488319 · Phase 3 · registry result, not featured evidence |
| PANSS General Psychopathology absolute change · score No placebo or comparator arm | 0.19 score @ 330wke,a,b,f NCT00088465 · Phase 3 · registry result, not featured evidence | 27.9 score @ 26wke,a,b,f NCT01724359 · Phase 4 · registry result, not featured evidence |
| PANSS Total absolute change · score No placebo or comparator arm | 0.3 score @ 330wka,b,g NCT00088465 · Phase 3 · registry result, not featured evidence | -12.6 score @ 104wkd,a,b,g NCT00488319 · Phase 3 · registry result, not featured evidence show 2 more doses-22.4 score @ 104wk NCT00488319 · Phase 3 · registry result, not featured evidence -18.9 score @ 104wk NCT00488319 · Phase 3 · registry result, not featured evidence |
| Time to Relapse Median time to event · months | 17.71 vs 20.48 Oral Olanzapine months*a,b,h NCT00320489 · Phase 3 · monotherapy · converted to months from 539 days as posted | NA vs 1.61 placebo monthsd,a,b,h NCT01662310 · Phase 3 · registry result, not featured evidence show 1 more doseNA vs 1.71 placebo months NCT01662310 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 54.9%i NCT00320489 · Phase 3 · monotherapy show 1 more result60.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 41.2%i NCT00784238 · Phase 4 · registry result, not featured evidence show 35 more results48.4% NCT00761579 · Phase 4 · registry result, not featured evidence 36.4% NCT00761605 · Phase 4 · registry result, not featured evidence 20% NCT01387542 · Phase 4 · registry result, not featured evidence 11.3% NCT01362439 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Extension Phase NCT01010776 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Main Phase NCT01010776 · Phase 4 · registry result, not featured evidence 32.6% NCT01724359 · Phase 4 · registry result, not featured evidence 27.1% NCT01577186 · Phase 4 · registry result, not featured evidence 40.5% NCT00757705 · Phase 4 · registry result, not featured evidence 27.8% NCT01577160 · Phase 4 · registry result, not featured evidence —Paliperidone ER Phase NCT00535145 · Phase 4 · registry result, not featured evidence 25.4%Study Treatment NCT00535145 · Phase 4 · registry result, not featured evidence —TAU - Pali ER NCT00535145 · Phase 4 · registry result, not featured evidence 40%6 mg NCT00524043 · Phase 4 · registry result, not featured evidence 47%1.5 mg NCT00524043 · Phase 4 · registry result, not featured evidence 0%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 0%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —Paliperidone DB/Paliperidone Open- NCT01662310 · Phase 3 · registry result, not featured evidence —Paliperidone: Double Blind (DB) Ph NCT01662310 · Phase 3 · registry result, not featured evidence 36.4%Paliperidone (Double-blind)/Palipe NCT00488319 · Phase 3 · registry result, not featured evidence 50.2%Paliperidone (No Double-blind)/Pal NCT00488319 · Phase 3 · registry result, not featured evidence 38.5%Placebo/Paliperidone NCT00488319 · Phase 3 · registry result, not featured evidence 24.8% NCT01009047 · Phase 3 · registry result, not featured evidence 19.1% NCT01541371 · Phase 3 · registry result, not featured evidence 50% NCT00473434 · Phase 3 · registry result, not featured evidence 20.4% NCT00566631 · Phase 3 · registry result, not featured evidence — NCT00645099 · Phase 3 · registry result, not featured evidence 28.3%Paliperidone ER: Lack of Efficacy NCT01662648 · Phase 3 · registry result, not featured evidence 29.8%Paliperidone ER: Lack of Tolerabil NCT01662648 · Phase 3 · registry result, not featured evidence 22.9%Pali ER High NCT00518323 · Phase 3 · registry result, not featured evidence 35.2%Pali ER Low NCT00518323 · Phase 3 · registry result, not featured evidence 16.7%Pali ER Medium NCT00518323 · Phase 3 · registry result, not featured evidence 15.4% NCT01606228 · Phase 3 · registry result, not featured evidence 45.4% NCT01561898 · Phase 3 · registry result, not featured evidence 35.3% NCT00396565 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 9.8%i NCT00320489 · Phase 3 · monotherapy show 1 more result8.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 4.8%i NCT00784238 · Phase 4 · registry result, not featured evidence show 35 more results5.3% NCT00761579 · Phase 4 · registry result, not featured evidence 6.7% NCT00761605 · Phase 4 · registry result, not featured evidence 7.5% NCT01387542 · Phase 4 · registry result, not featured evidence 0.8% NCT01362439 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Extension Phase NCT01010776 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Main Phase NCT01010776 · Phase 4 · registry result, not featured evidence 10.5% NCT01724359 · Phase 4 · registry result, not featured evidence 4.8% NCT01577186 · Phase 4 · registry result, not featured evidence 6.4% NCT00757705 · Phase 4 · registry result, not featured evidence 2.5% NCT01577160 · Phase 4 · registry result, not featured evidence —Paliperidone ER Phase NCT00535145 · Phase 4 · registry result, not featured evidence 2.6%Study Treatment NCT00535145 · Phase 4 · registry result, not featured evidence —TAU - Pali ER NCT00535145 · Phase 4 · registry result, not featured evidence 2.9%6 mg NCT00524043 · Phase 4 · registry result, not featured evidence 10.6%1.5 mg NCT00524043 · Phase 4 · registry result, not featured evidence —PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —Paliperidone DB/Paliperidone Open- NCT01662310 · Phase 3 · registry result, not featured evidence —Paliperidone: Double Blind (DB) Ph NCT01662310 · Phase 3 · registry result, not featured evidence 1.7%Paliperidone (Double-blind)/Palipe NCT00488319 · Phase 3 · registry result, not featured evidence 9.5%Paliperidone (No Double-blind)/Pal NCT00488319 · Phase 3 · registry result, not featured evidence 2.6%Placebo/Paliperidone NCT00488319 · Phase 3 · registry result, not featured evidence 4.4% NCT01009047 · Phase 3 · registry result, not featured evidence 3.7% NCT01541371 · Phase 3 · registry result, not featured evidence 4.7% NCT00473434 · Phase 3 · registry result, not featured evidence 3.1% NCT00566631 · Phase 3 · registry result, not featured evidence — NCT00645099 · Phase 3 · registry result, not featured evidence 8.3%Paliperidone ER: Lack of Efficacy NCT01662648 · Phase 3 · registry result, not featured evidence 6.2%Paliperidone ER: Lack of Tolerabil NCT01662648 · Phase 3 · registry result, not featured evidence 2.1%Pali ER High NCT00518323 · Phase 3 · registry result, not featured evidence 1.9%Pali ER Low NCT00518323 · Phase 3 · registry result, not featured evidence 2.1%Pali ER Medium NCT00518323 · Phase 3 · registry result, not featured evidence 0.5% NCT01606228 · Phase 3 · registry result, not featured evidence 14.4% NCT01561898 · Phase 3 · registry result, not featured evidence 3.7% NCT00396565 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 9.5%i NCT00320489 · Phase 3 · monotherapy show 1 more result18.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 7.3%i NCT00784238 · Phase 4 · registry result, not featured evidence show 35 more results12.1% NCT00761579 · Phase 4 · registry result, not featured evidence 9.8% NCT00761605 · Phase 4 · registry result, not featured evidence 2.5% NCT01387542 · Phase 4 · registry result, not featured evidence 0.8% NCT01362439 · Phase 4 · registry result, not featured evidence 1.9%Paliperidone ER - Extension Phase NCT01010776 · Phase 4 · registry result, not featured evidence 6.5%Paliperidone ER - Main Phase NCT01010776 · Phase 4 · registry result, not featured evidence 7.4% NCT01724359 · Phase 4 · registry result, not featured evidence 7.7% NCT01577186 · Phase 4 · registry result, not featured evidence 3.7% NCT00757705 · Phase 4 · registry result, not featured evidence 0% NCT01577160 · Phase 4 · registry result, not featured evidence 2.4%Paliperidone ER Phase NCT00535145 · Phase 4 · registry result, not featured evidence —Study Treatment NCT00535145 · Phase 4 · registry result, not featured evidence 0%TAU - Pali ER NCT00535145 · Phase 4 · registry result, not featured evidence 7.1%6 mg NCT00524043 · Phase 4 · registry result, not featured evidence 10.6%1.5 mg NCT00524043 · Phase 4 · registry result, not featured evidence 4%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 3.1%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 4.3%Paliperidone DB/Paliperidone Open- NCT01662310 · Phase 3 · registry result, not featured evidence 3.1%Paliperidone: Double Blind (DB) Ph NCT01662310 · Phase 3 · registry result, not featured evidence 3.4%Paliperidone (Double-blind)/Palipe NCT00488319 · Phase 3 · registry result, not featured evidence 18.9%Paliperidone (No Double-blind)/Pal NCT00488319 · Phase 3 · registry result, not featured evidence 23.1%Placebo/Paliperidone NCT00488319 · Phase 3 · registry result, not featured evidence 6.2% NCT01009047 · Phase 3 · registry result, not featured evidence 0.2% NCT01541371 · Phase 3 · registry result, not featured evidence 42.2% NCT00473434 · Phase 3 · registry result, not featured evidence 7.8% NCT00566631 · Phase 3 · registry result, not featured evidence 8.8% NCT00645099 · Phase 3 · registry result, not featured evidence 6.8%Paliperidone ER: Lack of Efficacy NCT01662648 · Phase 3 · registry result, not featured evidence 4.9%Paliperidone ER: Lack of Tolerabil NCT01662648 · Phase 3 · registry result, not featured evidence 2.1%Pali ER High NCT00518323 · Phase 3 · registry result, not featured evidence 3.7%Pali ER Low NCT00518323 · Phase 3 · registry result, not featured evidence 2.1%Pali ER Medium NCT00518323 · Phase 3 · registry result, not featured evidence 2.1% NCT01606228 · Phase 3 · registry result, not featured evidence — NCT01561898 · Phase 3 · registry result, not featured evidence 3% NCT00396565 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | show 1 more resultweight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence | i akathisia 8.3% extrapyramidal disorder 4.8% insomnia 4.8% NCT00784238 · Phase 4 · registry result, not featured evidence show 33 more resultsakathisia 18.4% weight increased 15.3% muscle rigidity 7.4% NCT00761579 · Phase 4 · registry result, not featured evidence insomnia 12.4% akathisia 11.4% weight increased 9.3% NCT00761605 · Phase 4 · registry result, not featured evidence drowsiness 15% headache 15% insomnia 12.5% NCT01387542 · Phase 4 · registry result, not featured evidence insomnia 3% weight increase 3% extrapyramidal symptoms 2.3% NCT01362439 · Phase 4 · registry result, not featured evidence weight increased 12.6% insomnia 8.8% depression 4.4% NCT01010776 · Phase 4 · registry result, not featured evidence insomnia 14.9% anxiety 10.7% weight increased 10.7% NCT01010776 · Phase 4 · registry result, not featured evidence insomnia 25.3% akathisia 23.2% parkinsonism 15.8% NCT01724359 · Phase 4 · registry result, not featured evidence extrapyramidal disorder 11.7% upper respiratory tract infection 6.7% tremor 4.8% NCT01577186 · Phase 4 · registry result, not featured evidence insomnia 20.7% extrapyramidal disorder 13.7% anxiety 11.7% NCT00757705 · Phase 4 · registry result, not featured evidence insomnia 15.9% constipation 11.3% extrapyramidal disorder 9.6% NCT01577160 · Phase 4 · registry result, not featured evidence weight increased 6% headache 3.6% akathisia 2.4% NCT00535145 · Phase 4 · registry result, not featured evidence 6 mg headache 11.4% (placebo 15.6%) insomnia 10% (placebo 9.4%) tremor 10% (placebo 3.1%) NCT00524043 · Phase 4 · registry result, not featured evidence 1.5 mg insomnia 13.6% (placebo 9.4%) dizziness 7.6% (placebo 1.6%) headache 7.6% (placebo 15.6%) NCT00524043 · Phase 4 · registry result, not featured evidence constipation 9.1% insomnia 9.1% somnolence 8.1% NCT00535132 · Phase 4 · registry result, not featured evidence insomnia 9.2% headache 8.2% constipation 6.1% NCT00535132 · Phase 4 · registry result, not featured evidence constipation 4.3% (placebo 3.4%) akathisia 2.1% (placebo 5.1%) headache 2.1% (placebo 1.7%) NCT01662310 · Phase 3 · registry result, not featured evidence akathisia 4.7% (placebo 5.1%) nausea 3.1% (placebo 0%) tremor 3.1% (placebo 0%) NCT01662310 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.3% somnolence 15.3% tremor 10.2% NCT00488319 · Phase 3 · registry result, not featured evidence weight increased 24.3% headache 18.9% somnolence 18.5% NCT00488319 · Phase 3 · registry result, not featured evidence somnolence 25.6% insomnia 17.9% anxiety 10.3% NCT00488319 · Phase 3 · registry result, not featured evidence akathisia 11.5% headache 10.6% somnolence 10.6% NCT01009047 · Phase 3 · registry result, not featured evidence akathisia 18.4% tremor 12.9% dystonia 8.7% NCT01541371 · Phase 3 · registry result, not featured evidence insomnia 15.6% headache 10.9% akathisia 9.4% NCT00473434 · Phase 3 · registry result, not featured evidence insomnia 23.1% tachycardia 8.5% headache 7.5% NCT00566631 · Phase 3 · registry result, not featured evidence insomnia 9.6% weight increased 9.6% headache 4.6% NCT00645099 · Phase 3 · registry result, not featured evidence insomnia 9.8% extrapyramidal disorder 6.6% headache 4.5% NCT01662648 · Phase 3 · registry result, not featured evidence insomnia 11.6% headache 4.1% nausea 3.9% NCT01662648 · Phase 3 · registry result, not featured evidence somnolence 20.8% (placebo 2%) akathisia 16.7% (placebo 0%) insomnia 12.5% (placebo 21.6%) NCT00518323 · Phase 3 · registry result, not featured evidence headache 9.3% (placebo 3.9%) insomnia 9.3% (placebo 21.6%) schizophrenia 9.3% (placebo 7.8%) NCT00518323 · Phase 3 · registry result, not featured evidence somnolence 14.6% (placebo 2%) akathisia 8.3% (placebo 0%) tremor 8.3% (placebo 0%) NCT00518323 · Phase 3 · registry result, not featured evidence insomnia 13.3% anemia 4.8% acute psychotic symptoms 1.6% NCT01606228 · Phase 3 · registry result, not featured evidence schizophrenia 16.4% (placebo 42.8%) insomnia 11.2% (placebo 10.1%) nasopharyngitis 10.4% (placebo 8%) NCT00396565 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 104 weeks versus 313 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 4 versus Phase 3.
- fAssessment timepoints differ: 26 weeks versus 330 weeks.
- gAssessment timepoints differ: 104 weeks versus 330 weeks.
- hThe assessment timepoint is not available for both results.
- iPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olanzapine (Zyprexa Relprevv)
+ 10 further endpoints in the CSV export.
Paliperidone (Invega)
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 3 more results
show 2 more results
show 2 more results
show 25 more results
+ 64 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Paliperidone (Invega)'s landscape